Liposome-encapsulated daunorubicin-cytarabine and venetoclax for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs packaged in a special fat coating (liposome) plus a targeted pill called venetoclax for adults with acute myeloid leukemia (AML) that has come back, not responded, or is newly diagnosed. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (or between 18 and 69 if you have not been treated for AML before).
- You have acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed and you have not received prior therapy (for one part of the study).
- Your liver and kidney function must be within certain limits (tests will be done to check).
- Your heart function must be at least 45% (measured by an echo or similar test) and you must not have severe heart disease.
- You must not be pregnant or breastfeeding, and if you are able to have children, you must agree to use effective contraception during the study.
- You must not have a specific type of AML called acute promyelocytic leukemia (M3) or core-binding factor AML, and you must not have active leukemia in the spinal fluid or brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.